Skip to main content

Table 1 The main baseline characteristics for eligible patients divided by MACEs-related situation

From: Association between the triglyceride-glucose index and 1-year major adverse cardiovascular events in patients with coronary heart disease and hypertension

Indicators

Overall

MACEs

Non-MACEs

P value

N

810

379

431

 

Male (n, %)

571 (70.49)

277 (73.09)

294 (68.21)

0.129

Age (years)

66 (57, 74)

69 (61, 78)

63 (55, 70)

< 0.001

BMI (kg/m2)

24.97 (23.38, 27.22)

25.95 (24.27, 28.23)

24 (22.84, 25.96)

< 0.001

SBP (mmHg)

136 (123, 149)

139 (126, 156)

132 (122, 145)

< 0.001

DBP (mmHg)

79 (70, 86)

80 (70, 87)

79 (70, 85)

0.888

HR (bpm)

72 (68, 80)

76 (70, 82)

70 (66, 76)

< 0.001

Smoking (n, %)

358 (44.2)

168(44.33)

190 (44.08)

0.944

Drinking (n, %)

197 (24.32)

99 (26.12)

98 (22.74)

0.263

Case history (n, (%)

    

 Diabetes

403 (49.75)

203 (47.1)

200 (52.77)

0.107

 CKD a

114 (14.07)

85 (22.43)

29 (6.73)

< 0.001

 OMI

151 (18.64)

110 (29.02)

41 (9.51)

< 0.001

 Family history of CVDs

258 (31.85)

157 (41.42)

101 (23.43)

< 0.001

Number of coronary lesions (n, %)

    

 One-vessel disease

629 (77.65)

279 (73.61)

350 (81.21)

0.010

 Two-vessel disease

146 (18.02)

80 (21.11)

66 (15.31)

0.032

 Multi-vessel disease

35 (4.32)

20 (5.28)

15 (3.48)

0.210

Cardiovascular medications (n, %)

    

 Anti-platelet

809 (99.88)

379 (100)

430 (99.77)

0.348

 Statins

796 (98.27)

373 (98.42)

423 (98.14)

0.766

 ACEI/ARB

552 (68.15)

246 (64.91)

306 (71)

0.063

 β-blockers

613 (75.68)

298 (78.63)

315 (73.09)

0.067

 CCB

344 (42.47)

148 (39.05)

196 (45.48)

0.065

 Nitrates

251 (30.99)

113 (29.82)

138 (32.02)

0.499

Laboratory variables

    

 TC (mmol/L)

3.83 (3.2, 4.71)

3.76 (3.18, 4.98)

3.83 (3.24, 4.57)

0.290

 TG (mmol/L)

1.44 (1.06, 1.94)

1.65 (1.24, 2.04)

1.26 (1.03, 1.74)

< 0.001

 LDL-C (mmol/L)

2.28 (1.81, 2.86)

2.24 (1.71, 2.91)

2.26 (1.87, 2.78)

0.487

 HDL-C (mmol/L)

0.99 (0.83, 1.15)

0.95 (0.76, 1.1)

0.99 (0.87, 1.18)

0.002

 HCY (µmol/L)

14.11 (11.38, 17.97)

16.45(12.99, 21.75)

12.43 (10.7, 15.48)

< 0.001

 Hs-CRP (mg/L)

2.08 (0.97, 4.58)

3.45 (1.73, 9.13)

1.44 (0.71, 2.47)

< 0.001

 Scr (µmol/L)

75.8 (62.9, 90.3)

79.8 (65.48, 99.08)

72.5 (60.7, 84.3)

< 0.001

 FBG (mmol/L)

5.91 (5.13, 6.9)

6.23 (5.27, 7.51)

5.61 (5, 6.62)

< 0.001

 HbA1c (%)

6.2 (5.8, 7.1)

6.5 (5.9, 7.73)

6.1 (5.7, 6.8)

< 0.001

 TyG index

8.85 (8.48, 9.18)

9.07 (8.72, 9.29)

8.72 (8.41, 8.98)

< 0.001

PAD indicators

    

 baPWV (m/s)

17.2 (15.38, 22.1)

22.66 (20.63, 25.09)

15.48 (14.68, 16.21)

< 0.001

 ABI

1.08 (0.92, 1.17)

0.92 (0.8, 1)

1.16 (1.12, 1.2)

< 0.001

 FMD (%)

6.8 (6, 8)

6 (5.6, 6.4)

7.6 (7, 9)

< 0.001

Echocardiography

    

 LAD (mm)

38 (36, 40)

40 (37, 43)

37 (35, 38)

< 0.001

 LVDd (mm)

51 (48, 54)

53 (50, 56)

49 (46, 52)

< 0.001

 IVST (mm)

10 (9, 11)

11 (10, 12)

10 (9, 10)

< 0.001

 PWT (mm)

9 (8, 10)

10 (9, 10)

9 (8, 9)

< 0.001

 LVEF (%)

65 (60, 69)

61.5 (55, 67)

67 (63, 71)

< 0.001

  1. MACE, major adverse cardiovascular event; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; CKD, chronic kidney disease; OMI, old myocardial infarction; CVD, cardiovascular disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blockers; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HCY, homocysteine; Hs-CRP, hypersensitive C-reactive protein; Scr, serum creatinine; FBG, fasting blood glucose; HbA1c, glycosylated hemoglobin; TyG, triglyceride-glucose; PAD, peripheral artery disease; baPWV, brachial-ankle pulse wave velocity; ABI, ankle-brachial index; FMD, brachial artery flow-mediated vasodilatation; LAD, left atrial diameter; LVDd, left ventricular end-diastolic diameter; IVST, interventricular septal thickness; PWT, left ventricular posterior wall thickness; LVEF, left ventricular ejection fraction
  2. a Defined as eGFR < 60 ml/min/1.73 m2 on the basis of The KDIGO CKD Clinical Guideline